Home Newsfeeds Celularity Q2 EPS $0.32

Celularity Q2 EPS $0.32

Celularity (NASDAQ:CELU) reported quarterly earnings of $0.32 per share.

byBill Haddad

August 9, 2022

1 minute read

Celularity (NASDAQ:CELU) reported quarterly earnings of $0.32 per share.

Microsoft’s Strategic Emphasis on AI and Cloud Services Signals Strong Future Performance: Analysts

By Anusuya Lahiri

April 18, 2:56 PM

Citigroup analyst maintains Microsoft with a Buy and lowered price target from $480 to $475, expecting strong Azure growth, while BofA analyst reiterates Buy with $480 target.

IXN

Stratasys Confirms Receipt Of Revised Unsolicited Proposal From 3D Systems To Acquire Stratasys For $7.50 In Cash And 1.5444 Newly Issued Shares Of 3D Systems Common Stock Per Ordinary Share Of Stratasys

By Happy Mohamed

July 13, 10:57 AM

Stratasys Ltd. (NASDAQ:SSYS) ("Stratasys" or the "Company"), a leader in polymer 3D printing solutions, today confirmed that it has received a revised unsolicited proposal from 3D Systems Corporation

DDD

Pfizer And Valneva Announce That Pfizer, As The Study Sponsor, Has Decided To Discontinue A Significant Percentage Of Participants In The U.S. Who Had Been Enrolled In The Valor Phase 3 Study, Due To Violations Of Good Clinical Practice

By Benzinga Newsdesk

February 17, 4:32 AM

The study is investigating the efficacy, safety, and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15. These study participants, representing approximately half of the total recruited

PFE

Nio Stock Continues To Climb: What’s Going On?

By Adam Eckert

July 31, 9:36 AM

NIO Inc (NYSE: NIO) shares are trading higher Monday, adding to gains of more than 25% over the last week.

NIO

Celularity Q2 EPS $0.32

Related Posts

Microsoft’s Strategic Emphasis on AI and Cloud Services Signals Strong Future Performance: Analysts

Stratasys Confirms Receipt Of Revised Unsolicited Proposal From 3D Systems To Acquire Stratasys For $7.50 In Cash And 1.5444 Newly Issued Shares Of 3D Systems Common Stock Per Ordinary Share Of Stratasys

Pfizer And Valneva Announce That Pfizer, As The Study Sponsor, Has Decided To Discontinue A Significant Percentage Of Participants In The U.S. Who Had Been Enrolled In The Valor Phase 3 Study, Due To Violations Of Good Clinical Practice

Nio Stock Continues To Climb: What’s Going On?